<DOC>
	<DOCNO>NCT01190462</DOCNO>
	<brief_summary>RATIONALE : Monoclonal antibody , cetuximab , block tumor growth different way . Some block ability tumor cell grow spread . Others find tumor cell help kill carry tumor-killing substance . Simvastatin may stop growth tumor cell block enzymes need cell growth . Simvastatin may help cetuximab work well make tumor cell sensitive cetuximab . Giving cetuximab together simvastatin may kill tumor cell . PURPOSE : This phase II trial study give cetuximab together simvastatin treat patient advanced metastatic colorectal cancer .</brief_summary>
	<brief_title>Cetuximab Simvastatin Treating Patients With Advanced Metastatic Colorectal Cancer</brief_title>
	<detailed_description>OBJECTIVES : Primary - To determine percentage patient k-ras mutant , advanced metastatic colorectal cancer free progression alive 12.5 week follow first dose cetuximab combination simvastatin . Secondary - To determine correlation overall response rate , progression-free survival , overall survival , safety skin toxicity efficacy . - To determine predictive value PTEN , PIK3CA , b-raf , ERK MEK status . ( exploratory ) - To determine predictive value SNPs , proteomics , circulate DNA . ( exploratory ) - To evaluate cholesterol , proteomics , circulate DNA biomarkers set . ( exploratory ) OUTLINE : This multicenter study . Patients receive cetuximab IV weekly oral simvastatin daily day 1-7 . Courses repeat every 7 day absence disease progression unacceptable toxicity . Blood sample collect laboratory study baseline , study , completion study . After completion study therapy , patient follow 30 day .</detailed_description>
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<mesh_term>Cetuximab</mesh_term>
	<mesh_term>Simvastatin</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Diagnosis advance metastatic colorectal cancer Progressive disease past 3 month Failed prior oxaliplatin , fluorouracil ( 5FU ) , irinotecancontaining regimen AND presence kras mutation within codon 12 , 13 , 61 PATIENT CHARACTERISTICS : WHO performance status 02 Adequate organ function No history toxicity statin use No malignancy within past 5 year No history severe pulmonary disease No clinically relevant coronary artery disease PRIOR CONCURRENT THERAPY : See Disease Characteristics No prior epidermal growth factor receptor ( EGFR ) target agent No concurrent verapamil amiodarone</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2011</verification_date>
	<keyword>recurrent colon cancer</keyword>
	<keyword>stage III colon cancer</keyword>
	<keyword>stage IV colon cancer</keyword>
	<keyword>recurrent rectal cancer</keyword>
	<keyword>stage III rectal cancer</keyword>
	<keyword>stage IV rectal cancer</keyword>
</DOC>